Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy

Treatment of cancer with EGFR inhibitors is limited by on-target skin toxicities induced by inhibition of the MAPK pathway. BRAF inhibitors are known to paradoxically activate the MAPK downstream of EGFR, which we confirmed using human skin keratinocytes. We then conducted a phase I clinical trial t...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacouture, Mario E., Wainberg, Zev A., Patel, Anisha B., Anadkat, Milan J., Stemmer, Salomon M., Shacham-Shmueli, Einat, Medina, Egmidio, Zelinger, Galit, Shelach, Noa, Ribas, Antoni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Research Brief
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418997/
https://www.ncbi.nlm.nih.gov/pubmed/33910927
http://dx.doi.org/10.1158/2159-8290.CD-20-1847

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418997/
https://www.ncbi.nlm.nih.gov/pubmed/33910927
http://dx.doi.org/10.1158/2159-8290.CD-20-1847

Ejemplares similares